Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13917733 | 0.81 | PDE4A (0.62) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL3064788 | 0.81 | PDE4A (0.44) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL27677822 | 0.81 | OR51E2 (0.42) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL21143414 | 0.81 | TDP1 (0.62) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL7775006 | 0.81 | PDE4A (0.44) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL3064781 | 0.81 | PDE4A (0.44) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL3073651 | 0.81 | PDE4A (0.44) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL1895730 | 0.81 | PDE4A (0.44) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL3901335 | 0.81 | TDP1 (0.50) | PDE4AOR51E2USP2SLCO1B1TDP1 | |
| SCHEMBL3130940 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190646-A1 | Compositions Comprising Thalidomide and Artemisinin for the Treatment of Cancer | DAFRA PHARMA N.V. (BE) | 2012-07-26 | — | — | US | claimed |
| EP-2289554-A1 | Compositions comprising thalidomide and artemisinin for the treatment of cancer | Dafra Pharma N.V. (BE) | 2011-03-02 | — | — | EP | claimed |
| WO-2011012626-A1 | COMPOSITIONS COMPRISING THALIDOMIDE AND ARTEMISININ FOR THE TREATMENT OF CANCER | DAFRA PHARMA N.V. (BE) | 2011-02-03 | — | — | WO | claimed |
| US-20120190646-A1 | Compositions Comprising Thalidomide and Artemisinin for the Treatment of Cancer | DAFRA PHARMA N.V. (BE) | 2012-07-26 | — | — | US | disclosed |
| EP-2289554-A1 | Compositions comprising thalidomide and artemisinin for the treatment of cancer | Dafra Pharma N.V. (BE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011012626-A1 | COMPOSITIONS COMPRISING THALIDOMIDE AND ARTEMISININ FOR THE TREATMENT OF CANCER | DAFRA PHARMA N.V. (BE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190646-A1 | Compositions Comprising Thalidomide and Artemisinin for the Treatment of Cancer | CD47, THPO, MLLT1 | PDE4A 3040/4885OR51E2 4504/4885USP2 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.